|
CN105168228A
|
|
Compound composition of obeticholic acid and berberine and applications thereof
|
|
CN104940902A
|
|
Polyethylene glycol consensus interferon mutant stabilization solution
|
|
WO2015096595A1
|
|
Pegylated interferon derivative and pharmaceutical composition thereof
|
|
CN105085658A
|
|
Interleukin 29 mutant and polyethylene glycol derivative
|
|
CN105085657A
|
|
Interferon mutant and polyethylene glycol derivative
|
|
CN103923209A
|
|
Lambda interferon mutant and polyethylene glycol derivative
|
|
CN103936847A
|
|
Polyethylene glycol-SA (PEG-SA) and medicinal composition thereof
|
|
CN105054068A
|
|
Saccharomyces cerevisiae glutathione nutritional preparation
|
|
CN103704723A
|
|
Nutritional preparation rich in active amino acids
|
|
CN103304566A
|
|
Novel crystalline entecavir
|
|
CN103224917A
|
|
Method for recovering SAMe synthetase activity
|
|
CN103304551A
|
|
Hepatitis C polymerase inhibitor
|
|
CN102327241A
|
|
Polyethylene glycol-integrated interferon variant freeze-dried preparation
|
|
CN102327242A
|
|
Polyethylene glycol-integrated interferon variant lyophilized preparation
|
|
CN102321643A
|
|
Optimized DNA (Deoxyribonucleic Acid) molecule for coding ADI (Aiginine Deiminase) and engineering bacteria for expressing ADI
|
|
CN102145178A
|
|
PEG interleukin 15
|
|
CN102584979A
|
|
Polyethylene glycol (PEG) interferon lambda
|
|
CN102008447A
|
|
Entecavir solid dispersion and preparation thereof
|
|
CN102008446A
|
|
Pirfenidone solid dispersion and preparation thereof
|
|
CN102475697A
|
|
Preparation of ornithine aspartate for injection
|
